StockData

Compass Therapeutics vs Cardiff Oncology

CMPX and CRDF side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CMPX and CRDF compare

Compass Therapeutics is the larger company, worth 1.7 times as much as Cardiff Oncology ($109M against $65.8M).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCMPXCRDF
Size and price
Market cap$109M$65.8M
Share price$0.607$0.846
Change, 1 year−87.4%−60.3%
Change, 5 years−81.2%−84.9%
Beta (5Y)2.202.50
Employees3931
StockData Score
Total score77
Valuation score1 (better)0
Growth score01 (better)
Performance score11
Health score55
Dividend score00
Valuation
P/S–130×
P/B0.7× (better)2.5×
FCF yield−51.6%–
Growth
Revenue growth (TTM)–−7.0%
Revenue growth, 5Y average–10.1%
Profitability
Operating margin–−8320%
Net margin–−7884%
Return on equity−56.7% (better)−94.1%
Financial health
Debt / equity0.000.00
Current ratio11.22 (better)3.30
Altman Z-score−1.14 (better)−16.20
Piotroski F-score3 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions92.0%24.2%
Held by insiders26.3%4.9%
Insider net buying, 12 months$96.8K$1.1M (better)
Short interest, % of float30.7%16.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.